FMP
Biofrontera Inc.
BFRI
NASDAQ
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
0.979 USD
-0.0215 (-2.2%)
About
ceo
Dr. Hermann Luebbert Ph.D.
sector
Healthcare
industry
Drug Manufacturers - Specialty & Generic
exchange
NASDAQ
Description
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
CIK
0001858685
ISIN
US09077D2099
CUSIP
09077D100
Address
120 Presidential Way
Phone
781 245 1325
Country
US
Employee
83
IPO Date
Oct 29, 2021
Key Executives
